PropertyValue
?:abstract
  • The ongoing coronavirus disease 2019 pandemic has forced the clinical and scientific community to try drug repurposing of existing antiviral agents as a quick option against severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2). Under this scenario, interferon (IFN) β-1a, whose antiviral potential is already known, and which is a drug currently used in the clinical management of multiple sclerosis, may represent as a potential candidate. In this report, we demonstrate that IFN-β-1a was highly effective in inhibiting in vitro SARS-CoV-2 replication at clinically achievable concentration when administered after virus infection.
?:creator
?:doi
  • 10.1093/infdis/jiaa350
?:doi
?:journal
  • J_Infect_Dis
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/9a9ab3b59eab45dd271f7b701f3030c70699c199.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7337790.xml.json
?:pmcid
?:pmid
?:pmid
  • 32559285.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC; WHO
?:title
  • Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome–Coronavirus 2 In Vitro When Administered After Virus Infection
?:type
?:year
  • 2020-06-19

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/8g40ukml>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/8g40ukml>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all